Cyclosporin A inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 3, 2005, Pages 782-790

  Eckstein, Lauren A ^a   Van Quill, Kurtis R ^a   Bui, Steven K ^b   Uusitalo, Marita S ^c   O'Brien, Joan M ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UCSF Department of Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN ALPHA; CALCINEURIN BETA; CYCLOSPORIN A; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; FK 506 BINDING PROTEIN 12.6; LIPOCORTIN 5; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSCRIPTION FACTOR NFATC3; UNCLASSIFIED DRUG; VALSPODAR; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; CASPASE; CASPASE 3; CASPASE 7; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; DNA BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NFATC1 PROTEIN, HUMAN; NFATC3 PROTEIN, HUMAN; NUCLEAR PROTEIN; TACROLIMUS;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; RETINA TUMOR; T LYMPHOCYTE;

APOPTOSIS; BLOTTING, WESTERN; CALCINEURIN; CASPASE 3; CASPASE 7; CASPASES; CYCLOSPORINE; CYCLOSPORINS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; NFATC TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; RETINAL NEOPLASMS; RETINOBLASTOMA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 16244385639     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1022     Document Type: Article

References (69)

1. Gurney JG, Smith MA, Ross JA. Cancer among infants. In: Ries LAG, Smith MA, Gurney JG, et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995 (SEER Pediatric Monograph). Bethesda, MD: National Cancer Institute, SEER Program. NIH Pub. No. 99-4649;1999:149-156.
2. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643-646.
3. Lee W-H, Bookstein R, Hong F, Young L-J, Shew J-Y, Lee EY-HP. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987;235:1394-1399.
4. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278: 1262-1267.
5. Greenwald MJ, Strauss LC. Treatment of intraocular retinoblastoma with carboplatin and etoposide chemotherapy. Ophthalmology. 1996;103:1989-1997.
6. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1348-1356.
7. Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1330-1338.
8. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology. 1997;104:2101-2111.
9. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12-17.
10. Chan HSL, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2:1499-1508.
11. Gallic BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 1996;114:1321-1328.
12. Bosch I, Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta. 1996;1288:F37-54.
13. Chan HSL, Thorner PS, Haddad G, Gallic BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. 1991;98:1425-1431.
14. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol. 1992;43:109-117.
15. Kashani-Sabet M, Lu Y, Leong L, Haedicke K, Scanlon KJ. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer. 1990;26:383-390.
16. Scanlon KJ, Wang WZ, Han H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev. 1990;17 Suppl A:27-35.
17. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246:339-346.
18. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313-326.
19. Nork TM, Schwartz TL, Doshi HM, Millecchia LL. Retinoblastoma: cell of origin. Arch Ophthalmol. 1995;113:791-802.
20. Lee TW, Yang SW, Kim CM, Hong WS, Youn DH. Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines. J Korean Med Sci. 1993;8:104-109.
21. McDonald JW, Goldberg MP, Gwag BJ, Chi SI, Choi DW. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol. 1996;40:750-758.
22. Kaminska B, Figiel I, Pyrzynska B, Czajkowski R, Mosieniak G. Treatment of hippocampal neurons with cyclosporin A results in calcium overload and apoptosis which are independent on NMDA receptor activation. Br J Pharmacol. 2001;133:997-1004.
23. Mosieniak G, Figiel I, Kaminska B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J Neurochem. 1997;68:1142-1149.
24. Mosieniak G, Pyrzynska B, Kaminska B. Nuclear factor of activated T cells (NFAT) as a new component of the signal transduction pathway in glioma cells. J Neurochem. 1998;71:134-141.
25. Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem (Tokyo). 2002;131:1-15.
26. Goto S, Matsukado Y, Mihara Y, Inoue N, Miyamoto E. Calcineurin as a neuronal marker of human brain tumors. Brain Res. 1986; 371:237-243.
27. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-142.
28. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science. 1988;241:202-205.
29. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, Calcineurin, and NFAT. Genes Dev. 2003;17:2205-2232.
30. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(suppl):S67-S79.
31. Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol. 2002;156:771-774.
32. McCaffrey PG, Luo C, Kerppola TK, et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science. 1993; 262:750-754.
33. Northrop JP, Ho SN, Chen L, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369:497-502.
34. Hoey T, Sun YL, Williamson K, Xu X. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity. 1995;2:461-472.
35. Masuda ES, Naito Y, Tokumitsu H, et al. NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus. Mol Cell Biol. 1995;15:2697-2706.
36. Ho SN, Thomas DJ, Timmerman LA, Li X, Francke U, Crabtree GR. NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem. 1995;270:19898-19907.
37. Lopez-Rodriguez C, Aramburu J, Rakeman AS, Rao A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc Natl Acad Sci USA. 1999;96:7214-7219.
38. Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 1991;51:4226-4233.
39. Demeule M, Wenger RM, Béliveau R. Molecular interactions of cyclosporin A with P-glycoprotein: photolabeling with cyclosporin derivatives. J Biol Chem. 1997;272:6647-6652.
40. Atadja P, Watanabe T, Xu H, Cohen D. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev. 1998;17:163-168.
41. Hooks MA. Tacrolimus, a new immunosuppressant. a review of the literature. Ann Pharmacother. 1994;28:501-511.
42. Shapiro VS, Mollenauer MN, Greene WC, Weiss A. c-rel regulation of IL-2 gene expression may be mediated through activation of AP-1. J Exp Med. 1996;184:l663-l669.
43. Shapiro VS, Truitt KE, Imboden JB, Weiss A. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol Cell Biol. 1997;17:4051-4058.
44. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273:239-242.
45. Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996; 76:631-649.
46. Clardy J. The chemistry of signal transduction. Proc Natl Acad Sci USA. 1995;92:56-61.
47. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, Bourgeois S. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol. 1995;15:4395-4402.
48. Baughman G, Wiederrecht GJ, Chang F, Martin MM, Bourgeois S. Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition. Biochem Biophys Res Commun. 1997;232:437-443.
49. Wiederrecht G, Hung S, Chan HK, et al. Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. J Biol Chem. 1992; 267:21753-21760.
50. Lopez-Rodriguez C, Aramburu J, Jin L, et al. Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity. 2001;15: 47-58.
51. Lyakh L, Ghosh P, Rice NR. Expression of NFAT-family proteins in normal human T cells. Mol Cell Biol. 1997;17:2475-2484.
52. Durand DB, Shaw JP, Bush MR, Replogle RE, Belagaje R, Crabtree GR. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol Cell Biol. 1988;8:1715-1724.
53. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science. 1989;246:1617-1620.
54. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991;352:803-807.
55. Krishnakumar S, Kandalam M, Desai N, et al. Multidrug-resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 2004;88:1521-1526.
56. Begley DJ, Squires LK, Zlokovic BV, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem. 1990;55:1222-1230.
57. Cunha-Vaz JG. The blood-retinal barriers. Doc Ophthalmol. 1976; 41:287-327.
58. Madigan MC, Penfold PL. Human retinoblastoma: a morphological study of apoptotic, leukocytic, and vascular elements. Ultrastruct Pathol. 1997;21:95-107.
59. Ohnishi Y, Yamana Y, Minei M, Ibayashi H. Application of fluorescein angiography in retinoblastoma. Am J Ophthalmol. 1982;93: 578-588.
60. Shields JA, Sanborn GE, Augsburger JJ, Orlock D, Donoso LA. Fluorescein angiography of retinoblastoma. Retina. 1982;2:206-214.
61. Abramson DH, Frank CM, Chantada GL, et al. Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. Ophthalmic Genet. 1999;20:31-36.
62. Lehne G, Rugstad HE. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein. Br J Cancer. 1998;78:593-600.
63. Azare J, Pankova-Kholmyansky I, Salnikow K, Cohen D, Flescher E. Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein. Oncol Res. 2000;12:315-323.
64. Duraj J, Takacsova X, Sedlak J, et al. PSC 833 induces apoptosis in drug-sensitive human leukemia cell line and modulates resistance to paclitaxel in its multidrug-resistant variant. Anticancer Res. 2000;20:4627-4632.
65. Lopes EC, Garcia M, Benavides F, et al. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Leuk Res. 2003;27:413-423.
66. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia. 1999;13:768-778.
67. Gallic B, Study Chair. A Randomized Trial of Cyclosporine Modulation of Chemotherapy with Focal Therapy for Bilateral Retinoblastoma for the Child with Large Retinoblastoma in at Least One Eye (Z0080). Funded by American College of Surgeons Oncology Group, 1998.
68. Chan H, Gallic B, Principal Investigators. Phase II Study of High Dose Chemotherapy with Cyclosporine for Vision-Threatening Intraocular Retinoblastoma. Funded by Ontario Cancer Research Network, 2002.
69. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity. 2000;12: 359-372.